Effectiveness of Adjuvanted Recombinant Zoster Vaccine (RZV) Against Postherpetic Neuralgia (PHN) and Against Cardiovascular Disease (CVD) Events After Herpes Zoster (HZ) in United States Adults in Medicare Fee-for-Service (FFS) + Inovalon’s MORE2 Registry (307298 - EPI-ZOSTER-116 VE DB US)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001125
• Study ID:
  1000001125
• Official title and acronym:
  Effectiveness of Adjuvanted Recombinant Zoster Vaccine (RZV) Against Postherpetic Neuralgia (PHN) and Against Cardiovascular Disease (CVD) Events After Herpes Zoster (HZ) in United States Adults in Medicare Fee-for-Service (FFS) + Inovalon’s MORE2 Registry (307298 - EPI-ZOSTER-116 VE DB US)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Planned

Research institutions and networks

Institutions

GlaxoSmithKline Biologicals SA

Inovalon

Study timelines

Date when funding contract was signed

Planned:28/01/2026

Actual:28/01/2026

Study start date

Planned:28/09/2026

Date of final study report

Planned:02/09/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable